Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.

El Hassouni B, Mantini G, Li Petri G, Capula M, Boyd L, Weinstein HNW, Vallés-Marti A, Kouwenhoven MCM, Giovannetti E, Westerman BA, Peters GJ; EORTC PAMM Group.

Anticancer Res. 2019 Jul;39(7):3303-3309. doi: 10.21873/anticanres.13472. Review.

PMID:
31262850
2.

The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.

Saleem H, Kulsoom Abdul U, Küçükosmanoglu A, Houweling M, Cornelissen FMG, Heiland DH, Hegi ME, Kouwenhoven MCM, Bailey D, Würdinger T, Westerman BA.

Drug Resist Updat. 2019 Mar;43:29-37. doi: 10.1016/j.drup.2019.04.002. Epub 2019 Apr 22.

3.

WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.

Abdul KU, Houweling M, Svensson F, Narayan RS, Cornelissen FMG, Küçükosmanoglu A, Metzakopian E, Watts C, Bailey D, Wurdinger T, Westerman BA.

Drug Resist Updat. 2018 Sep;40:17-24. doi: 10.1016/j.drup.2018.10.001. Epub 2018 Oct 30. Review.

PMID:
30439622
4.

Cross-Tissue Transcriptomic Analysis of Human Secondary Lymphoid Organ-Residing ILC3s Reveals a Quiescent State in the Absence of Inflammation.

Bar-Ephraim YE, Cornelissen F, Papazian N, Konijn T, Hoogenboezem RM, Sanders MA, Westerman BA, Gönültas M, Kwekkeboom J, Den Haan JMM, Reijmers RM, Mebius RE, Cupedo T.

Cell Rep. 2017 Oct 17;21(3):823-833. doi: 10.1016/j.celrep.2017.09.070.

5.

Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.

Narayan RS, Gasol A, Slangen PLG, Cornelissen FMG, Lagerweij T, Veldman HYYE, Dik R, van den Berg J, Slotman BJ, Würdinger T, Haas-Kogan DA, Stalpers LJA, Baumert BG, Westerman BA, Theys J, Sminia P.

Mol Cancer Ther. 2018 Feb;17(2):347-354. doi: 10.1158/1535-7163.MCT-17-0480. Epub 2017 Sep 27.

6.

Neuroblastoma is composed of two super-enhancer-associated differentiation states.

van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, van Noesel CJM, Jongejan A, van Kampen AH, Koster L, Baas F, van Dijk-Kerkhoven L, Huizer-Smit M, Lecca MC, Chan A, Lakeman A, Molenaar P, Volckmann R, Westerhout EM, Hamdi M, van Sluis PG, Ebus ME, Molenaar JJ, Tytgat GA, Westerman BA, van Nes J, Versteeg R.

Nat Genet. 2017 Aug;49(8):1261-1266. doi: 10.1038/ng.3899. Epub 2017 Jun 26.

PMID:
28650485
7.

The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.

Narayan RS, Fedrigo CA, Brands E, Dik R, Stalpers LJ, Baumert BG, Slotman BJ, Westerman BA, Peters GJ, Sminia P.

BMC Cancer. 2017 Mar 21;17(1):204. doi: 10.1186/s12885-017-3193-9.

8.

Blood-brain barrier crossing and breakthroughs in glioblastoma therapy.

Sminia P, Westerman BA.

Br J Clin Pharmacol. 2016 Jun;81(6):1018-20. doi: 10.1111/bcp.12881. Epub 2016 Feb 8. No abstract available.

9.

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.

Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren H, Post E, Koster J, Ylstra B, Ameziane N, Dorsman J, Smit EF, Verheul HM, Noske DP, Reijneveld JC, Nilsson RJA, Tannous BA, Wesseling P, Wurdinger T.

Cancer Cell. 2015 Nov 9;28(5):666-676. doi: 10.1016/j.ccell.2015.09.018. Epub 2015 Oct 29.

10.

GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors.

Westerman BA, Blom M, Tanger E, van der Valk M, Song JY, van Santen M, Gadiot J, Cornelissen-Steijger P, Zevenhoven J, Prosser HM, Uren A, Aronica E, van Lohuizen M.

PLoS One. 2012;7(5):e35943. doi: 10.1371/journal.pone.0035943. Epub 2012 May 4.

11.

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R.

Nature. 2012 Feb 22;483(7391):589-93. doi: 10.1038/nature10910.

PMID:
22367537
12.

A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation.

Westerman BA, Braat AK, Taub N, Potman M, Vissers JH, Blom M, Verhoeven E, Stoop H, Gillis A, Velds A, Nijkamp W, Beijersbergen R, Huber LA, Looijenga LH, van Lohuizen M.

J Exp Med. 2011 Dec 19;208(13):2675-89. doi: 10.1084/jem.20102037. Epub 2011 Dec 5.

13.

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.

Huang S, Laoukili J, Epping MT, Koster J, Hölzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, Versteeg R, Beijersbergen RL, Bernards R.

Cancer Cell. 2009 Apr 7;15(4):328-40. doi: 10.1016/j.ccr.2009.02.023.

14.

Bmi1 is required for Hedgehog pathway-driven medulloblastoma expansion.

Michael LE, Westerman BA, Ermilov AN, Wang A, Ferris J, Liu J, Blom M, Ellison DW, van Lohuizen M, Dlugosz AA.

Neoplasia. 2008 Dec;10(12):1343-9, 5p following 1349.

15.

Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors.

Westerman BA, Breuer RH, Poutsma A, Chhatta A, Noorduyn LA, Koolen MG, Postmus PE, Blankenstein MA, Oudejans CB.

Int J Biol Markers. 2007 Apr-Jun;22(2):114-23.

PMID:
17549667
16.

The parent-of-origin effect of 10q22 in pre-eclamptic females coincides with two regions clustered for genes with down-regulated expression in androgenetic placentas.

Oudejans CB, Mulders J, Lachmeijer AM, van Dijk M, Könst AA, Westerman BA, van Wijk IJ, Leegwater PA, Kato HD, Matsuda T, Wake N, Dekker GA, Pals G, ten Kate LP, Blankenstein MA.

Mol Hum Reprod. 2004 Aug;10(8):589-98. Epub 2004 Jun 18.

PMID:
15208369
18.

NEUROD1 acts in vitro as an upstream regulator of NEUROD2 in trophoblast cells.

Westerman BA, Chhatta A, Poutsma A, van Vegchel T, Oudejans CB.

Biochim Biophys Acta. 2004 Jan 5;1676(1):96-103.

PMID:
14732494
19.

The cellular Pax-Hox-helix connection.

Westerman BA, Murre C, Oudejans CB.

Biochim Biophys Acta. 2003 Oct 1;1629(1-3):1-7. Review.

PMID:
14522074
20.

Detection of chromosome 21-encoded mRNA of placental origin in maternal plasma.

Oudejans CB, Go AT, Visser A, Mulders MA, Westerman BA, Blankenstein MA, van Vugt JM.

Clin Chem. 2003 Sep;49(9):1445-9.

21.

Circulating trophoblast in maternal blood.

Oudejans CB, Tjoa ML, Westerman BA, Mulders MA, Van Wijk IJ, Van Vugt JM.

Prenat Diagn. 2003 Feb;23(2):111-6. Review.

PMID:
12575016
22.

Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.

Westerman BA, Neijenhuis S, Poutsma A, Steenbergen RD, Breuer RH, Egging M, van Wijk IJ, Oudejans CB.

Clin Cancer Res. 2002 Apr;8(4):1082-6.

23.

The proneural genes NEUROD1 and NEUROD2 are expressed during human trophoblast invasion.

Westerman BA, Poutsma A, Maruyama K, Schrijnemakers HF, van Wijk IJ, Oudejans CB.

Mech Dev. 2002 Apr;113(1):85-90.

24.

The Human Achaete Scute Homolog 2 gene contains two promotors, generating overlapping transcripts and encoding two proteins with different nuclear localization.

Westerman BA, Poutsma A, Looijenga LH, Wouters D, van Wijk IJ, Oudejans CB.

Placenta. 2001 Jul;22(6):511-8.

PMID:
11440538

Supplemental Content

Loading ...
Support Center